ALX Oncology Holdings Inc.

06/12/2025 | Press release | Distributed by Public on 06/12/2025 14:20

Proxy Results (Form 8-K)

Item 5.07 Submission of matters to a vote of security holders.

ALX Oncology Holdings Inc. (the "Company") held its Annual Meeting of stockholders (the "Annual Meeting") on June 11, 2025. The matters voted upon at the Annual Meeting and the voting results for each proposal are set forth below.

Proposal 1: Election of Two Class II Directors

Name of Director

For

Withheld

Broker Non-Votes

Scott Garland

23,602,975

8,662,965

11,796,795

Barbara Klencke, M.D.

30,835,565

1,430,375

11,796,795

Each director nominee was duly elected to serve until the 2028 annual meeting of stockholders and until their successor is duly elected and qualified, subject to earlier resignation or removal.

Proposal 2: Advisory Vote on the Compensation of the Company's Named Executive Officers

For

Against

Abstain

Broker Non-Votes

22,147,884

8,736,683

1,381,373

11,796,795

The stockholders approved, on an advisory basis, the compensation paid to the Company's named executive officers, as disclosed in the proxy statement for the Annual Meeting.

Proposal 3: Ratification of the Appointment of Independent Registered Public Accounting Firm

For

Against

Abstain

41,776,769

59,969

2,225,997

The stockholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.

1

ALX Oncology Holdings Inc. published this content on June 12, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on June 12, 2025 at 20:20 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at support@pubt.io